Value Star Asset Management Hong Kong Ltd Boosts Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Value Star Asset Management Hong Kong Ltd lifted its stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 25.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,000 shares of the company's stock after acquiring an additional 2,000 shares during the period. HCA Healthcare accounts for about 22.4% of Value Star Asset Management Hong Kong Ltd's investment portfolio, making the stock its largest position. Value Star Asset Management Hong Kong Ltd's holdings in HCA Healthcare were worth $3,456,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in HCA. Congress Wealth Management LLC DE grew its holdings in HCA Healthcare by 3.4% in the 4th quarter. Congress Wealth Management LLC DE now owns 1,039 shares of the company's stock valued at $312,000 after buying an additional 34 shares during the last quarter. Evergreen Private Wealth LLC boosted its position in shares of HCA Healthcare by 0.3% in the fourth quarter. Evergreen Private Wealth LLC now owns 12,787 shares of the company's stock valued at $3,838,000 after acquiring an additional 35 shares during the period. Whittier Trust Co. increased its position in HCA Healthcare by 3.6% during the fourth quarter. Whittier Trust Co. now owns 1,195 shares of the company's stock worth $359,000 after acquiring an additional 41 shares during the period. Barden Capital Management Inc. grew its position in HCA Healthcare by 1.4% in the 1st quarter. Barden Capital Management Inc. now owns 2,921 shares of the company's stock worth $1,009,000 after purchasing an additional 41 shares during the last quarter. Finally, Coldstream Capital Management Inc. raised its position in shares of HCA Healthcare by 1.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 3,471 shares of the company's stock valued at $1,042,000 after buying an additional 44 shares during the last quarter. Institutional investors own 62.73% of the company's stock.

HCA Healthcare Price Performance

HCA Healthcare stock opened at $377.26 on Monday. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $417.14. The firm has a market cap of $90.76 billion, a P/E ratio of 16.77, a P/E/G ratio of 1.30 and a beta of 1.49. The company has a debt-to-equity ratio of 69.07, a quick ratio of 1.06 and a current ratio of 1.19. The business's fifty day moving average is $362.30 and its two-hundred day moving average is $334.94.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.75 by $0.70. HCA Healthcare had a net margin of 8.07% and a return on equity of 1,063.91%. The firm had revenue of $18.32 billion during the quarter, compared to analysts' expectations of $18.26 billion. During the same quarter last year, the company posted $5.36 EPS. The company's quarterly revenue was up 5.7% compared to the same quarter last year. Equities research analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 16th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.76%. The ex-dividend date is Monday, June 16th. HCA Healthcare's dividend payout ratio (DPR) is presently 12.81%.

Analysts Set New Price Targets

HCA has been the topic of several research reports. Baird R W lowered HCA Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 15th. Wells Fargo & Company upgraded HCA Healthcare from an "underweight" rating to an "equal weight" rating and upped their target price for the company from $320.00 to $385.00 in a research note on Thursday, May 29th. Barclays set a $416.00 price target on shares of HCA Healthcare and gave the stock an "overweight" rating in a research note on Monday, June 2nd. Wall Street Zen upgraded shares of HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Monday, April 28th. Finally, Robert W. Baird reissued a "neutral" rating and issued a $336.00 price target (down previously from $396.00) on shares of HCA Healthcare in a research report on Tuesday, April 15th. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, HCA Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $392.47.

Insider Buying and Selling

In other news, COO Jon M. Foster sold 15,698 shares of HCA Healthcare stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the completion of the sale, the chief operating officer now owns 12,646 shares in the company, valued at $4,670,420.72. The trade was a 55.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.30% of the company's stock.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.